Roche's Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma

Erivedge is a new medicine that helps people with a disfiguring and potentially life-threatening form of skin cancer. Roche announced today that the European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news